Nĩ kyaũ kĩtonya kũiita mũndũ ũla wĩ na kanza ya prostate?
Ve nzĩa syĩ kĩvathũkany'o sya ũiiti wa kanza ya prostate, na ũiiti ũsu wĩthĩawa wĩ kĩvathũkany'o kwosana na ũwau ũla ũwaĩte, ũwau ũla wĩ naw'o, na ũndũ ũendeee.
No ĩtũmĩwe nĩ aũme ala me na ũwau ũte mũthũku wa kanza ya prostate.
2. Kũthĩnw'a: Mũndũ athĩnw'a nĩ kana aumye ĩvu ya mũndũũme yĩtawa prostate.
Mũndũ no athĩnzwe na nzĩa ĩsu ya kũtila kana ya laparoscopy.
3. Ũiiti wa kũiita na kyeni (radiation therapy): Ũiiti ũũ ũtũmĩaa kyeni kingĩ mũno kya kyeni nĩ kana kĩkoae tũsamũ twa kanza.
No ĩnengwe mũndũ e na ũwau mũna (kwa kũtũmĩa masinĩ yĩthĩawa yĩ nza wa mwĩĩ) kana ĩkamwĩkĩwa vandũ ve na ũwau (kwa kũmwĩkĩa kĩndũ kĩ na ũwau vakuvĩ na vala ve ũwau ũsu).
4. Ũiiti wa hormone: Ũiiti ũsu ũtumaa hormone sya mũndũũme (androgens) ila syĩ mwĩĩnĩ wa mũndũũme iola na ũu ũituma kanza ya prostate ĩeka kwĩana kana ĩoleka kwĩana.
No ĩtũmĩwe yĩ yoka kana yĩ na ndawa ingĩ.
5. Ũiiti wa chemotherapy: Ũiiti ũũ ũtũmĩaa ndawa sya kũaa tũsamũ twa kanza.
No ĩtũmĩwe kũiita mũndũ ũwaĩte kanza ya kĩthũi yĩ vandũ yĩendeee na yĩnyaĩĩka mamuthanĩ angĩ ma mwĩĩ.
6. Ũiiti wa kũsiĩĩa mowau: Ũiiti ũsu nũtumaa mwĩĩ ũsinda mowau ala matonya kũũmĩsya mwĩĩ.
No ĩtũmĩwe kũiita andũ ala me na ũwau mũthũku wa kanza ya kĩthũi (prostate cancer) na matatetheew'a nĩ ndawa ingĩ.
7. Ũiiti ũla ũtũmĩaa tũla twĩndũ tũnini (targeted therapy): Ũiiti ũsu ũtũmĩaa tũla twĩndũ tũnini (genes) kana tũla twĩndũ tũnini (proteins) tũtetheeasya ĩmũndũ yĩ na kanza yĩane na yĩyĩkala thayũ.
No ĩtũmĩwe kũiita andũ ala me na ũwau mũthũku wa kanza ya kĩthũi (prostate cancer) na matatetheew'a nĩ ndawa ingĩ.
8. Kũiitwa na mbevo mbingĩ (cryotherapy): Mũndũ no atũmĩe mbevo mbingĩ mũno nĩ kana avetange na ayũaa twĩndũ tũla twĩ na kanza.
No ĩtũmĩwe kũiita andũ ala me na kanza ya kĩthũi kana mamutha ma mwĩĩ ala mambĩĩe kũwaa tene na mavĩndũka ĩtina wa kũiitwa na nzĩa ingĩ.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Ũtao:']
["Kĩsese kĩĩ kĩseũvĩtw'e kwondũ wa kũmanyĩsya na kũtetheesya andũ, ĩndĩ ti kũnengane motao ma ũiiti kana ũtethyo ũngĩ."]
['Ũvoo ũla wĩ vo ndwaĩle kũtũmĩwa kũĩkĩĩthya kana mũndũ e na ũwau mũna, na ala mekwenda ũtao wa ũiiti maĩle kũneena na ndakĩtalĩ.']
["Kwa ngelekany'o, ĩla mũndũ wakũlya ĩkũlyo yĩ na namba, no amanye kana mũndũ ũsu e na ũwau mũna."]
['Kĩla ĩvinda neena na ndakĩtalĩ waku kana mũndũ ũngĩ ũsomeete maũndũ ma ũiiti. Ndũkaatate kũlea kana kũkua ĩvinda ũimũkũlya ũtao aĩ nũndũ wa maũndũ amwe wasoma Kĩsesenĩ kĩĩ. Ethĩwa wĩona ta wĩ na thĩna wa mĩtũkĩ, neena na namba ya 911 kana ũthi sivitalĩ ya mĩtũkĩ ĩla yĩ vakuvĩ.']
['Ũtao:']
['The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) nĩyaĩtye kana ala me na ũthasyo wa kumĩthya syĩndũ ila syĩ Indanetinĩ nĩmaĩle kũtata ũndũ matonya nĩ kana maĩkĩĩthye kana syĩndũ ila mekumĩthya nĩsyavĩnga mĩao ya nthĩ ya Amelika.']
['Ethĩwa wĩ na mũĩkĩĩo kana ũvoo ũla wĩ kĩsesenĩ kitũ kana nthĩnĩ wa syĩndũ ila tumasya nũvĩtĩsye mĩao yaku, no ũtũtũmĩe valũa ũũtwĩĩte kana no ũtũsiĩĩe tũikamĩsome.']
["Mĩao ya DMCA yaĩtye kana no nginya ũvoo ũla ũũtũmĩa kũtũtavya kana ve kĩndũ kĩna kĩnavĩnga mĩao ya kumĩthya syĩndũ wĩthĩwe na ũvoo ũũ: (1) ũvoo ĩũlũ wa syĩndũ ila iwetetwe kana nĩsyo ivĩngĩĩsiwe nĩ mĩao ĩsu; (2) ũvoo ĩũlũ wa syĩndũ ila iwetetwe kana nĩsyo ivĩngĩĩsiwe nĩ mĩao ĩsu na ũvoo ũtonya kũtũtetheesya kũmanya vala syĩndũ isu syĩ; (3) ũndũ ũtonya kũtũtavya ũndũ ũtonya kũtũtavya ũndũ ũtonya kũũkũlya, ta vala wĩkalaa, namba yaku ya simũ, na valũa waku wa simũ; (4) ũĩkĩĩthyo ũkwonany'a kana wĩ na mũĩkĩĩo kana syĩndũ ila iwetetwe vau iyĩtĩkĩlĩtw'e nĩ ũla wĩ na ũthasyo wa kũseũvya syĩndũ, kana nĩ mũũngamĩi wasyo, kana nĩ mĩao ĩngĩ."]
["(5) ũĩkĩĩthyo kuma kwaku, ũla ũandĩkĩte ũikĩa ũkũsĩ ũte wa w'o, kana ũvoo ũla wĩ nthĩnĩ wa livoti nĩ wa w'o na kana wĩ na ũkũmũ wa kũũngamĩa maũndũ ala mawetwa nĩ ũla ũkũũmĩw'a;"]
['Na (6) saii ya mwene syĩndũ kana mũndũ ũla ũnengetwe ũkũmũ wa kwĩka maũndũ kwondũ wake.']
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
